Fundraising FoxNewpath Partners — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Rinascera Therapeutics develops treatments for rare genetic skin diseases, with drug candidates targeting conditions such as Gorlin Syndrome and Dystrophic Epidermolysis Bullosa.
BiotechHealthtechBoston, US
Nichola Eliovits(Executive Officer, Director)Max Dawson(Executive Officer)inKarl Beutner(Executive Officer, Director)
Board seatDaniel Yadegar· per SEC Form D · $2.5M raise · filed Oct 2025
Co-investorsOlive Tree Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.